Takeda
Better Health, Brighter Future
About Takeda
Funding & Growth
✓ Pros
- • Strong rare disease and GI focus
- • Cambridge, MA location (US hub)
- • Values-driven culture
- • Good work-life balance
- • Growing data science investment
✗ Cons
- • Japanese corporate influence
- • Post-Shire acquisition integration
- • Some timezone challenges with HQ
- • Large company processes
🏢 Working Here
Takeda's US computational biology operations are centered in Cambridge, MA (Kendall Square - the primary US R&D hub), with additional sites in San Diego, CA and Deerfield, IL.
The Cambridge location houses Takeda's largest US R&D facility and is the heart of computational biology work covering rare diseases, oncology, GI inflammation, and early discovery.
Being in Kendall Square provides extraordinary access to MIT, Harvard, Broad Institute, and the densest concentration of bioinformatics talent globally.
Following the 2019 Shire acquisition, Takeda became a $30B+ company focused on rare diseases, oncology, GI, and neuroscience.
Bioinformaticians work on rare disease genetics (hemophilia, Fabry, Hunter syndrome), GI inflammation (ulcerative colitis, Crohn's), oncology (multiple myeloma), and cell/gene therapies.
Takeda's culture blends Japanese values (patient focus, integrity, long-term thinking) with Western pharma operations and Boston biotech innovation.
The Cambridge location enables collaboration with top academic medical centers and access to cutting-edge single-cell/spatial genomics platforms.
🧬 Bioinformatics Focus
Takeda's computational biology spans rare diseases, GI inflammation, and oncology. Key areas:
- Rare disease genetics - analyzing ultra-rare patient cohorts for genetic diagnosis, understanding disease mechanisms for hemophilia, Fabry disease, Hunter syndrome, developing gene therapy approaches,
- GI inflammation - multi-omic analysis of IBD patients for Entyvio and next-gen therapies, microbiome integration, predicting treatment response,
- Multiple myeloma - analyzing samples from venetoclax combinations and novel agents, understanding plasma cell biology, resistance mechanisms,
- Cell and gene therapy - analyzing CAR-T and gene therapy manufacturing data, patient response biomarkers,
- Plasma - derived therapies - analyzing donor genetics and product composition, optimizing manufacturing through computational approaches. Takeda's acquisition history (Millennium, Shire) brought diverse computational capabilities. The company maintains patient registries for rare diseases providing longitudinal data. Technical challenges include analyzing small patient cohorts with statistical rigor (rare diseases), integrating Japanese and Western patient data accounting for genetic ancestry, and developing biomarkers for complex biologics like plasma-derived products.
📈 Career Growth & Development
Career Paths
Scientist Track
Leadership Track
Compensation
Competitive US salaries with 15-20% bonuses and stock grants are offered. Cambridge location commands premium pay.
Development
Professional development is supported through training, conferences, and external collaborations. The company encourages publications, particularly for rare disease work.
Mobility
Internal mobility across US sites and internationally to Japan/Switzerland is possible.
Culture
Takeda values both technical depth and cultural fit, emphasizing alignment with Takeda values.
Growth
The post-Shire integration created numerous advancement opportunities as the company builds integrated capabilities.
Expertise
Many computational biologists specialize in rare diseases, GI immunology, or oncology, with a unique focus on rare disease research.
💊 Top Medicines & Blockbuster Drugs
Entyvio (vedolizumab)
2014Indication: Ulcerative colitis and Crohn's disease
Gut-selective integrin inhibitor - #1 in IBD
Annual Revenue (USD)
Vyvanse (lisdexamfetamine)
2007Indication: ADHD and binge eating disorder
Shire acquisition - lost exclusivity 2023
Annual Revenue (USD)
Adcetris (brentuximab vedotin)
2011Indication: Hodgkin lymphoma and anaplastic large cell lymphoma
Antibody-drug conjugate - Seagen partnership
Annual Revenue (USD)
Ninlaro (ixazomib)
2015Indication: Multiple myeloma - oral proteasome inhibitor
First oral proteasome inhibitor
Annual Revenue (USD)
Alunbrig (brigatinib)
2017Indication: ALK-positive non-small cell lung cancer
Next-generation ALK inhibitor
Annual Revenue (USD)